20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Inclusion Criteria:

- Diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision (DSM-IV-TR) schizophrenia

- Total score on the PANSS Marder Negative Symptom Factor Scale (NSFS) ≥ 20

- Total score on the PANSS Marder Positive Symptom Factor Scale (PSFS) ≤ 30

- Receiving stable antipsychotic therapy for at least 8 weeks prior to screening

- Receiving a stable dose of other psychotropic agents for at least 8 weeks prior to
screening

- Subject has had a stable residence or living arrangement for at least 8 weeks prior
to screening and the residence or living arrangement is not anticipated to change for
the duration of the study

- The subject or subject's legally acceptable representative has provided informed
consent.

Exclusion Criteria:

- Current schizoaffective or bipolar disorder, panic disorder, obsessive compulsive
disorder, evidence of mental retardation by history or clinical examination or known
premorbid IQ ≤ 70

- Clinically significant suicidal ideation or suicide attempts, assaultive behavior or
marked changes in mood within the 8 weeks prior to screening, or currently endorsing
suicidal ideation in clinical exam

- Substance abuse (with the exception of nicotine or caffeine abuse) within the 8 weeks
prior to screening, or during screening

- Substance dependence (with the exception of nicotine or caffeine dependence) within
the 6 months prior to screening, or during screening

- Planning to initiate a smoking cessation therapy or otherwise substantially modify
nicotine use during the study

- Positive urine drug test for substances of abuse (with the exception of positive
screens for prescribed agents such as benzodiazepines).

- Other criteria may apply